Login to Your Account

Other News To Note

Thursday, March 8, 2012
• Apexigen Inc., of Burlingame, Calif., granted an exclusive license to Gansu Duyiwei Biological Pharmaceutical Co. Ltd. (GDBP), of Longnan City, China, to develop and commercialize APX004 in China. The humanized monoclonal antibody is directed against VEGFR2 for the treatment of certain cancers and angiogenic diseases. GDBP assumes sole responsibility to research, develop and commercialize APX004 in China, with Apexigen retaining rights to the compound outside China and collaborating with GDBP to advance the development program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription